Topics:

Adalimumab Slows Progression of Erosive Hand OA

Adalimumab Slows Progression of Erosive Hand OA

FEATURED SEARCH TERM:   psoriatic arthritis




The tumor necrosis factor alpha blocker adalimumab can slow down progression of structural damage in erosive interphalangeal finger joint osteoarthritis, according to this double-blind, randomized placebo-controlled trial. Overall, adalimumab had no therapeutic effect on these hand osteoarthritis patients. The key predictor of erosive evolution appears to be soft tissue swelling.


RESULT:
Tumour necrosis factor blockade for the treatment of erosive osteoarthritis of the interphalangeal finger joints: a double blind, randomised trial on structure modification
Annals of the Rheumatic Diseases | Jun 1, 2012 (FREE FULL TEXT)





A recent randomized, placebo-controlled trial found that methotrexate had no disease-modifying effect in psoriatic arthritis. However, the trial design had issues, says the author of the report below, and other studies show methotrexate –  the most widely used medication for psoriatic arthritis – may have at least a moderate disease-modifying effect.


RESULT: Spondyloarthritis: Is methotrexate effective in psoriatic arthritis?
Nature Reviews Rheumatology | May 2, 2012 (FREE FULL TEXT)

 

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.